Skip to content

TVT Versus TOT in Urinary Stress Incontinence With No Intrinsic Sphincter Deficiency

PROSPECTIVE RANDOMIZED STUDY COMPARING TVT AND TOT IN FEMALE STRESS URINARY INCONTINENCE WITH NO INTRINSIC SPHINCTER DEFICIENCY

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01903590
Enrollment
100
Registered
2013-07-19
Start date
2013-06-30
Completion date
2014-06-30
Last updated
2014-07-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Female Urinary Stress Incontinence

Keywords

TVT,TOT,Randomized

Brief summary

The aim of this study is to compare trans-vaginal tape(TVT) and trans-obturator tape(TOT) procedure in female urinary stress incontinence with no intrinsic sphincter deficiency.

Detailed description

Patients with isolated stress incontinence attending to Dr Zekai Tahir Burak Woman Health Teaching and Research Hospital Urogynecology Department will be prospectively randomized,by a computer generated randomisation code,to the TVT or TOT. The patients will be aware of the type of the surgical procedure before the operation. Preoperative evaluation includes clinical history,urinanalysis,pelvic examination QoL assessment and urodynamic study. QoL included Urogenital Distress Inventory Short Form (UDI-6) and the Incontinence Impact Questionnaire Short Form( IIQ-7).Urodynamic study includes cystometry,urethral profilometry and Valsalva leak point pressure (VLPP).In all patients,pelvic floor defect will be evaluated according to the POP quantification (POPQ) staging.To diagnose the occult stress incontinence in patients with pelvic prolapse, a cough test after reducing the prolapse will be performed.Patients will be followed up at 6 and 12 months postoperatively.Objective cure is defined as a negative cough stress test .Negative cough stress test ,but occasional urine leakage during stress will be considered ''improved''. Postoperative subjective outcomes will be categorized as follows:cured (UDI-6 and IIQ-7 postoperative\<10), improved (UDI-6 and IIQ-7 if postoperative\>preoperative) and worsened (UDI-6 and IIQ-7 if postoperative\<preoperative).

Interventions

Sponsors

Zekai Tahir Burak Women's Health Research and Education Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

* Women with urinary stress incontinence with no intrinsic sphincter deficiency * Women with or without pelvic organ prolapse

Exclusion criteria

* Previous incontinence surgery * Urge incontinence or overactive bladder * Mixed incontinence * Intrinsic sphincter deficiency * Body mass index\>35 * Un-willing for randomisation

Design outcomes

Primary

MeasureTime frameDescription
Comparison of the efficiency of TVT and TOT in stress incontinence with no intrinsic deficiencyOne yearPostoperative UDI-6 and IIQ-7 \<10 and negative cough test will be defined as ''cured''

Secondary

MeasureTime frameDescription
Objective effectiveness by cough test at 6 and 12 th months postoperativelyOne yearA patient with a bladder filled 300 cc saline will cough and if no leakage of urine,the patient will be described as ''cured''.
Subjective effectiveness by UDI-6 and IIQ-7 at 6-12 th months postoperativelyOne yearPostoperative subjective outcomes will be categorized as follows:cured (UDI-6 and IIQ-7 postoperative\<10), improved (UDI-6 and IIQ-7 if postoperative\>preoperative) and worsened (UDI-6 and IIQ-7 if postoperative\<preoperative).
Short term and long term surgical complicationsOne yearBleeding,bladder and bowel perforation,mesh erosion etc..
The prevalence of voiding dysfunction at 1 and 12 th months postoperativelyOne yearPostoperative residual volume after first voiding \>100 cc ,difficulty in voiding will be described as ''voiding dysfunction''.

Countries

Turkey (Türkiye)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026